What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model

Rafferty, Ellen; McDonald, Wade; Osgood, Nathaniel D.; Doroshenko, Alexander; Farag, Marwa

doi:10.1016/j.jval.2020.10.004

Cited by 11 publications

(10 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the chosen cost-effectiveness threshold, which corresponds to the WHO–CHOICE 1×GPD per capita of each state, the vaccination campaigns were deemed highly cost-effective as the resulting ICERs fell below the thresholds [ 34 ]. These findings are also consistent with the ICER estimated by Rafferty et al in Alberta Province, Canada, which fell between I$7704 per QALY and I$8137 per QALY, for chickenpox vaccination in children aged between 12 months and 6 years, on a health care system’s perspective, and was below the chosen cost-effectiveness threshold of $30,000 per QALY [ 35 ]. Routine childhood vaccination against seasonal influenza was cost-effective at I$3075.5 per QALY to EUR 1667.4 per QALY from a third-party payer’s perspective in Germany, as estimated by Scholz et al [ 36 ].…”

Section: Discussionsupporting

confidence: 89%

Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence

et al. 2023

View full text Add to dashboard Cite

SARS-CoV-2 vaccination has been the most effective tool to prevent COVID-19, significantly reducing deaths and hospitalizations worldwide. Vaccination has played a huge role in bringing the COVID-19 pandemic under control, even as the inequitable distribution of vaccines still leaves several countries vulnerable. Therefore, organizing a mass vaccination campaign on a global scale is a priority to contain the virus spread. The aim of this systematic review was to assess whether COVID-19 vaccination campaigns are cost-effective with respect to no vaccination. A systematic literature search was conducted in the WHO COVID-19 Global literature database, PubMed, Web of Science, Embase, and Scopus from 2020 to 2022. Studies assessing the COVID-19 vaccination campaign cost-effectiveness over no vaccination were deemed eligible. The “Drummond’s checklist” was adopted for quality assessment. A synthesis of the studies was performed through the “dominance ranking matrix tool”. Overall, 10 studies were considered. COVID-19 vaccination was deemed cost-effective in each of them, and vaccination campaigns were found to be sustainable public health approaches to fight the health emergency. Providing economic evaluation data for mass vaccination is needed to support decision makers to make value-based and evidence-based decisions to ensure equitable access to vaccination and reduce the COVID-19 burden worldwide.

show abstract

Section: Discussionsupporting

confidence: 89%

Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence

et al. 2023

View full text Add to dashboard Cite

show abstract

“…To address current concerns in childhood vaccination, a range of issues were covered, singly or in various combinations: the effect of taking account of HZ [ 47 , 50 , 53 , 54 , 56 , 59 , 63 , 81 – 83 , 87 , 88 ], the effect of boosting [ 50 , 59 , 81 ], age at second dose [ 53 , 55 ], confining a universal programme to susceptible adolescents [ 64 ], or post exposure prophylaxis [ 31 ]. Some of the studies measuring QALYs focused on simpler issues: a standard programme without herd immunity or HZ [ 68 ], with a package including catchup [ 63 ], with measles, mumps and rubella (MMR) vaccine [ 84 , 85 ] or a simple two dose childhood programme [ 81 ].…”

Section: Resultsmentioning

confidence: 99%

Systematic review of economic evaluations of varicella vaccination programmes

et al. 2023

View full text Add to dashboard Cite

Objectives This study carried out a systematic literature review of economic evaluations of varicella vaccination programmes from the earliest publication to the present day, including programmes in the workplace and in special risk groups as well as universal childhood vaccination and catch up programmes. Methods Articles published from 1985 until 2022 were sourced from PubMed/Medline, Embase, Web of Science, NHSEED and Econlit. Eligible economic evaluations, which included posters and conference abstracts, were identified by two reviewers who scrutinised each other’s selections at both title and abstract and full report stages. The studies are described in terms of their methodological characteristics. Their results are aggregated by type of vaccination programme and the nature of the economic outcome. Results A total of 2575 articles were identified of which 79 qualified as economic evaluations. A total of 55 studies focused on universal childhood vaccination, 10 on the workplace and 14 on high risk groups. Twenty-seven studies reported estimates of incremental cost per quality-adjusted life year (QALY) gained, 16 reported benefit-cost ratios, 20 reported cost-effectiveness outcomes in terms of incremental cost per event or life saved and 16 reported cost-cost offset results. Most studies of universal childhood vaccination reported an increase in overall costs to health services, but often a reduction in cost from a societal perspective. Conclusions The evidence surrounding the cost-effectiveness of varicella vaccination programmes remains sparse with contrasting conclusions in some areas. Future research should particularly aim to encompass the impact of universal childhood vaccination programmes on herpes zoster among adults.

show abstract

“…The number of countries that have implemented UVV for children has steadily increased since the first programme was introduced almost 30 years ago. However, varying UVV strategies have been implemented over time and established programmes, both between and regionally within countries, differ in terms of the number of doses recommended (one or two), the type of varicella vaccine(s) recommended (monovalent, quadrivalent MMRV or both), the age at which the first dose is administered and the interval between doses where programmes include a two‐dose schedule 14,15 . A number of systematic reviews assessing the safety of varicella vaccines have been published over the last 40 years.…”

Section: Introductionmentioning

confidence: 99%

“…However, varying UVV strategies have been implemented over time and established programmes, both between and regionally within countries, differ in terms of the number of doses recommended (one or two), the type of varicella vaccine(s) recommended (monovalent, quadrivalent MMRV or both), the age at which the first dose is administered and the interval between doses where programmes include a two-dose schedule. 14,15 A number of systematic reviews assessing the safety of varicella vaccines have been published over the last 40 years. However, early reviews are based on a one-dose monovalent vaccine schedule, while more recent reviews are based on both one-and two-dose schedules using both the monovalent and quadrivalent MMRV vaccines.…”

Section: Introductionmentioning

confidence: 99%

Safety of varicella vaccination strategies: An overview of reviews

Ahern

Walsh

Paone

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

The safety of new vaccines under development as well as existing vaccines is a key priority for national and international public health agencies. A number of countries have implemented universal childhood varicella vaccination programmes over the past 30 years. However, strategies differ in terms of the number of doses, type of vaccine(s) recommended, age at vaccination and interval between doses for a twodose schedule. An overview of reviews was undertaken to assess the existing systematic review evidence of the safety of varicella vaccination strategies. The review was restricted to immunocompetent children aged 9 months to 6 years inclusive. A comprehensive search of databases, registries and grey literature was conducted up to 2 February 2022. Two reviewers independently screened, extracted data and assessed the methodological quality of included reviews. Overlap of included reviews was also assessed. A total of 17 reviews, incorporating both the monovalent varicella only and quadrivalent measles-mumps-rubella-varicella (MMRV) vaccines were included in the overview; six assessed the safety of one-dose strategies, four assessed the safety of two-dose strategies and 14 reviews did not specify the dosing strategy. The evidence suggests that mild local and systemic reactions are relatively common with varicella vaccination. Febrile seizures are also possible adverse effects of both the monovalent and quadrivalent MMRV vaccine, but serious adverse reactions are rare. While most reviews contained methodological flaws, and analysis by vaccine type and dosing strategy was restricted due to lack of detail in reporting of the reviews, there was clear and consistent evidence from a substantial evidence base, comprising 34 randomised controlled trials and 62 other primary studies/reviews, that varicella vaccination is safe.

show abstract

What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model

Cited by 11 publications

References 45 publications

Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence

Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence

Systematic review of economic evaluations of varicella vaccination programmes

Safety of varicella vaccination strategies: An overview of reviews

Contact Info

Product

Resources

About